Clinical Trial of Fei Re Qing Granules in the Treatment of Elderly Community-Acquired Pneumonia

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Fei Re Qing Granules in the Treatment of Elderly Community-Acquired Pneumonia

This study aims to evaluate the clinical efficacy of traditional Chinese medicine formula granules (Fei Re Qing Granules) in the treatment of elderly community-acquired pneumonia, establish a treatment protocol, and obtain high-level clinical evidence.

Study Overview

• Status: Not yet recruiting
• Conditions: Community-Acquired Pneumonia (CAP)
• Intervention / Treatment: Drug: Fei Re Qing Granules; Other: Routine standard treatments; Drug: Placebo granules

Detailed Description

This study evaluates the efficacy and safety of Fei Re Qing Granules for elderly community-acquired pneumonia (CAP) through a multicenter, randomized, double-blind, placebo-controlled trial.

Key elements of the trial include:

Design: Conducted across multiple centers, comparing treatment and placebo groups.

Participants: Patients aged 65-80 years diagnosed with CAP according to both Western and Traditional Chinese Medicine (TCM) diagnostic criteria.

Intervention:

Test group: Fei Re Qing Granules administered alongside standard CAP treatments.

Control group: Placebo granules matching the appearance and composition of the active granules, plus standard treatments.

Outcomes:

Primary efficacy indicator: Time to clinical stability. Secondary indicators: Symptom improvement, hospital stay length, and imaging-based inflammation resolution.

TCM-specific indicators assess syndrome improvements and integrate modern scoring methods (e.g., CURB-65).

Study Duration: Two 7-day treatment cycles with 12-week follow-ups. This trial seeks to establish robust evidence for integrating Fei Re Qing Granules into TCM-based CAP management strategies

• Study Type: Interventional
• Enrollment (Estimated): 120
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Minghang Wang, Doctor; Phone Number: +86 371 66248624; Email: wmh107hn@163.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Inpatients diagnosed with community-acquired pneumonia (CAP) according to the diagnostic criteria.
• Diagnosed with Phlegm-Heat Obstructing the Lungs syndrome based on Traditional Chinese Medicine (TCM).
• Aged ≥65 and ≤80 years, regardless of gender.
• Onset of illness within 72 hours.
• Clinical symptoms must include at least two of the following four primary。symptoms: cough, sputum production, dyspnea, and pleuritic chest pain.
• Voluntary participation and signed informed consent.

Exclusion Criteria:

• Patients with altered mental status, consciousness disorders, dementia, or psychiatric disorders.
• Patients requiring invasive mechanical ventilation or endotracheal intubation.
• Patients with conditions such as pleural effusion, bronchiectasis, active pulmonary tuberculosis, pulmonary abscess, lung cancer, asthma, or chronic obstructive pulmonary disease (COPD).
• Patients with neuromuscular diseases or those bedridden for long periods, posing a risk of aspiration.
• Patients with cancer, severe cardiovascular diseases (acute myocardial infarction, heart failure stage III or above), or severe liver and kidney diseases (e.g., cirrhosis, portal hypertension with variceal bleeding, dialysis, or kidney transplantation).
• Patients participating in other drug clinical trials or known to be allergic to the study medication.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Test group; The patients in the trial group received routine standard treatments, and oral Fei Re Qing Granules (One bag/time, 3 times/day).	Drug: Fei Re Qing Granules; Fei Re Qing Granules (Ingredients: Scutellaria baicalensis [Huang Qin], Trichosanthes kirilowii [Gua Lou], Forsythia suspensa [Lian Qiao], Fritillaria thunbergii [Zhe Bei Mu], etc.); Other: Routine standard treatments; Routine standard treatments
Placebo Comparator: Control group; The patients in the control group received routine standard treatments, and Placebo granules	Other: Routine standard treatments; Routine standard treatments; Drug: Placebo granules; The placebo granules are prepared using 5% of the active drug, ensuring consistency in appearance, weight, color, and odor with the Fei Re Qing Granules

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to Clinical Stability	The criteria for clinical stability require meeting all five of the following indicators: Body temperature ≤ 37.8°C for more than 24 hours; Resting heart rate ≤ 100 beats per minute; Resting respiratory rate ≤ 24 breaths per minute; Systolic blood pressure ≥ 90 mmHg; Oxygen saturation (SpO₂) ≥ 90% (or arterial oxygen partial pressure ≥ 60 mmHg on room air). During the treatment period, log cards will be issued to monitor and record vital signs (temperature, respiration, blood pressure, heart rate, and SpO₂) every 12 hours. The time to clinical stability will be calculated based on these records	From the start of treatment, the time is recorded until the patient reaches clinical stability, whichever came first, assessed up to 2 weeks.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Improvement of Clinical Symptoms	Improvement in clinical symptoms is defined as at least two of the four main clinical symptoms (cough, sputum production, pleuritic chest pain, and dyspnea) showing an improvement of at least one grade, with no worsening of the other symptoms. The grade of clinical symptoms is divided into four levels: None Mild Moderate Severe The number of cases with clinical symptom improvement is calculated as the ratio of improved cases to the total cases in each group.	Evaluations will be conducted on Day 0, Day 4, Day 7, Day 14 (or at discharge) and during follow-up at 4 weeks and 12 weeks.
Length of Hospital Stay	The length of hospital stay is calculated as the number of days from admission to when the patient meets the discharge criteria. Discharge Criteria include: Body temperature normal for more than 24 hours; Resting heart rate ≤ 100 beats/min; Resting respiratory rate ≤ 24 breaths/min; Systolic blood pressure ≥ 90 mmHg; Oxygen saturation ≥ 90% (or arterial oxygen partial pressure ≥ 60 mmHg on room air). If the patient can be transitioned to oral medication and does not require further management for complications or mental disorders, discharge may be considered.	From the start of treatment, the time is recorded until the patient discharge, whichever came first, assessed up to 2 weeks.
Confusion, Urea, Respiratory rate, Blood pressure, and Age ≥65 Score (CURB-65 score).	The Confusion, Urea, Respiratory rate, Blood pressure, and Age ≥65 Score (CURB-65 score) is a clinical tool used to assess the severity of community-acquired pneumonia (CAP) and the associated mortality risk based on five clinical indicators(On a 5-point scale, 5 is the worst and 0 is the best.): Confusion (assessed by changes in mental status) ：0-5 score Urea (blood urea nitrogen level >7 mmol/L) ：0-5 score Respiratory rate (≥30 breaths/min) ：0-5 score Blood pressure (systolic BP <90 mmHg or diastolic BP ≤60 mmHg) ：0-5 score Age (≥65 years) ：0-5 score The total score is calculated by adding points for each indicator, with a higher score indicating more severe disease and higher risk of mortality.	The CURB-65 score is assessed on Day 0, Day 4, Day 7, Day 14 (or at discharge) and during follow-up at 4 weeks and 12 weeks.
Traditional Chinese Medicine Syndrome Efficacy Evaluation	Based on the Guidelines for Clinical Research of Traditional Chinese Medicine New Drugs, each symptom is rated on a scale of None, Mild, Moderate, and Severe (4 levels). Primary symptoms (e.g., cough, sputum production, chest pain, and dyspnea) are scored 0, 2, 4, and 6 points, respectively. Secondary symptoms (e.g., fever, thirst, flushed face, yellow urine, constipation, and abdominal distention) are scored 0 or 1 point, depending on their presence or absence. For the Phlegm-Heat Obstructing the Lungs syndrome, the overall score is calculated by summing the points for primary and secondary symptoms before and after treatment. The treatment outcomes are classified into four levels: Clinical Recovery: Syndrome score reduction ≥95%. Significant Improvement: Syndrome score reduction ≥70%. Effective: Syndrome score reduction ≥30%. Ineffective: Syndrome score reduction <30%.	These evaluations will be carried out on Day 0, Day 4, Day 7, Day 14 (or at discharge).
Comprehensive Clinical Efficacy Assessment	Based on the Antimicrobial Drug Clinical Research Guidelines, the efficacy is classified into four levels: Clinical Recovery: At the end of treatment, the patient's clinical symptoms, signs, major laboratory tests, and microbiological tests have all returned to normal. Significant Improvement: At the end of treatment, the patient's condition has noticeably improved, but one of the four key indicators (symptoms, signs, laboratory tests, or microbiological tests) has not fully returned to normal. Progress: At the end of treatment, the patient's condition has shown some improvement, but not enough to be considered significant. Ineffective: At the end of treatment, the patient's condition has not improved or has worsened.	This evaluation will be conducted on Day 14 (or at discharge).
Modified Pneumonia Imaging Absorption Evaluation Scale	Chest imaging examinations will be performed on both groups of subjects before and after treatment, as well as at the end of the follow-up, to observe the changes in lung imaging. The degree of pneumonia absorption will be recorded using the evaluation scale. Evaluation Process: Two radiology experts will independently assess and score the imaging results, and the average score will be taken. Assessment Points: The evaluations will be conducted on Day 0, Day 7 (or at discharge), and at 12 weeks during follow-up. This method helps assess the extent of pneumonia absorption and track changes in lung conditions over time.	The evaluations will be conducted on Day 0, Day 7 (or at discharge), and at 12 weeks during follow-up.
Pathogen Clearance Rate	The microbiological results of both groups of patients during hospitalization will be recorded. Pathogen clearance is defined as follows: Clearance: If no pathogen is detected in more than three consecutive tests. Replacement: If the original pathogen is no longer detected and a new pathogen is identified. Not cleared: If the pathogen load does not decrease, or although the pathogen load has decreased, it has not been completely cleared.	This will be assessed at pre-treatment, Day 7, Day 14 (or at discharge) for each patient.
Readmission Rate	The readmission rate includes the all-cause readmission rate and pneumonia-related readmission rate: All-cause readmission refers to patients being readmitted for any disease, with the admission criteria based on relevant disease guidelines. Pneumonia-related readmission refers to patients being readmitted due to a recurrent lung infection, with admission criteria based on the "Chinese Guidelines for the Diagnosis and Treatment of Adult Community-Acquired Pneumonia (2016 edition)", using the CURB-65 score to determine the need for hospitalization.	The readmission rate will be assessed at 4 weeks and 12 weeks during follow-up, with a detailed record of the reasons for readmission.

Collaborators and Investigators

• Sponsor: Henan University of Traditional Chinese Medicine
• Collaborators: The First Affiliated Hospital of Henan university of CM; Third Affiliated Hospital of Henan University of Traditional Chinese Medicine
• Investigators: Study Chair: Jiansheng Li, Doctor, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine

Study record dates

Study Major Dates

• Study Start (Estimated): January 1, 2025
• Primary Completion (Estimated): May 1, 2025
• Study Completion (Estimated): June 1, 2025

Study Registration Dates

• First Submitted: December 14, 2024
• First Submitted That Met QC Criteria: December 18, 2024
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: December 18, 2024
• Last Verified: December 1, 2024

More Information

Terms related to this study

• Keywords: randomized controlled trial; traditional Chinese medicine; elderly community-acquired pneumonia (CAP); Fei Re Qing Granules
• Additional Relevant MeSH Terms: Respiratory Tract Infections; Infections; Respiratory Tract Diseases; Lung Diseases; Pneumonia
• Other Study ID Numbers: TCM for Elderly CAP

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No